Browse

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

An outbreak of diarrhea-causing parasite has grown to more than 1,000 cases, making it one of the nation’s largest such outbreaks in years.

An ARPA-H program to jump-start custom gene editing treatments was delayed by a change in administrations. Now seven labs will get sizable grants.